(19)
(11) EP 4 165 051 A1

(12)

(43) Date of publication:
19.04.2023 Bulletin 2023/16

(21) Application number: 21743321.8

(22) Date of filing: 10.06.2021
(51) International Patent Classification (IPC): 
C07D 519/00(2006.01)
A61K 31/5025(2006.01)
A61P 35/00(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 519/00; A61P 35/00; Y02A 50/30
(86) International application number:
PCT/US2021/036839
(87) International publication number:
WO 2021/252781 (16.12.2021 Gazette 2021/50)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 12.06.2020 US 202063038410 P

(71) Applicant: Incyte Corporation
Wilmington, DE 19803 (US)

(72) Inventors:
  • PAN, Jun
    Media, Pennsylvania 19063 (US)
  • BAI, Yu
    Claymont, Delaware 19703 (US)
  • WU, Liangxing
    Wilmington, Delaware 19808 (US)
  • YAO, Wenqing
    Chadds Ford, Pennsylvania 19317 (US)

(74) Representative: Carpmaels & Ransford LLP 
One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)

   


(54) IMIDAZOPYRIDAZINE COMPOUNDS WITH ACTIVITY AS ALK2 INHIBITORS